New COVID vaccine candidates tested in early safety trial
NCT ID NCT05037097
Summary
This early-stage study tested three new COVID-19 RNA vaccine candidates in 72 healthy adults. It aimed to check their safety and how well they trigger an immune response in people who have never been vaccinated and in those who received previous COVID vaccines. Participants received either one or two doses, and researchers measured antibody levels and monitored for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arcturus Investigational Site 101
Singapore, 169608, Singapore
-
Arcturus Investigational Site 201
Kansas City, Missouri, 64114, United States
-
Arcturus Investigational Site 202
Wichita, Kansas, 67207, United States
-
Arcturus Investigational Site 301
Diepkloof, Soweto, 1862, South Africa
Conditions
Explore the condition pages connected to this study.